Pharma Focus Asia

magazine-slider-imageGet Instant Latest E-Book
Repligen

LATEST NEWSRead more...

26

Jul 2024

Ractigen Secures FDA Rare Pediatric Disease Designation for RAG-18 in Duchenne Muscular Dystrophy Treatment

Ractigen Therapeutics a leader in small activating RNA therapies has received Rare Pediatric Disease Designation from the US Food and Drug Administration for its saRNA candidate RAG

26

Jul 2024

IASO Bio Secures NMPA Approval to Begin Trials for IASO-782 in Systemic Lupus Erythematosus (SLE)

IASO Biotechnology a company specializing in advanced cell therapy and antibody products has received approval from the National Medical Products Administration for its investigational new drug

26

Jul 2024

A.forall Secures FDA Approval for Fifth Generic Drug Application on First Submission Cycle

Aforalls US subsidiary Milla Pharmaceuticals Inc has introduced its generic version of PrecedexDexmedetomidine Hydrochloride Injection in mcg per mL and mcg per mL formulated

25

Jul 2024

Eisai and EcoNaviSta Forge Business Partnership to Develop a Dementia Care Ecosystem and Initiate Collaboration

Eisai Co Ltd and EcoNaviSta Inc have formed a strategic alliance to tackle dementia a significant challenge in Japans aging population Eisai a leader in dementia research and awareness and EcoNaviSta

25

Jul 2024

Pfizer Reveals Successful Phase 3 Outcomes for Hemophilia A Gene Therapy Candidate

Pfizer Inc has released positive topline results from the Phase AFFINE study which tested giroctocogene fitelparvovec a gene therapy for adults with moderately severe to severe hemophilia A

24

Jul 2024

BeiGene Launches U.S. Biologics Manufacturing and R&D Facility, Advancing Global Expansion to Serve More Patients

BeiGene Ltd a global oncology company has launched its flagship US facility at the Princeton West Innovation Campus in Hopewell NJ This advanced site features cuttingedge biologics

Solovpe

press releasesRead more...

26

Jul 2024

Breakthrough in gene therapy brings new hope to Glaucoma patients

Macquarie University researchers have identified a gene therapy that could help treat the eye disease glaucoma with potential applications for other neurodegenerative conditions such as Alzheimers disease Glaucoma may result in irreversible blindness over to years if left untreated Like Alzheimers...

26

Jul 2024

Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, a Proposed Biosimilar of Keytruda® (Pembrolizumab)

BioThera Solutions Inc a commercialstage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars today announced that dosing has recently begun in an integrated Phase I

26

Jul 2024

Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development

Innovent Biologics Inc a worldclass biopharmaceutical company that develops manufactures and commercializes highquality medicines for the treatment of oncology cardiovascular and metabolic

26

Jul 2024

ObvioHealth announces strategic investment by Guardant Health to accelerate deployment of oncology clinical trials globally

ObvioHealth a global digital clinical trials company announces a new strategic investment by Guardant Health Inc a leading precision oncology company offering liquid

25

Jul 2024

Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, a Proposed Biosimilar to Stelara® in the US and EU

BioThera Solutions Inc a commercialstage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars today announced that the FDA has accepted the BLA for BAT a proposed

25

Jul 2024

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

NanoViricides Inc a clinical stage global leader in broadspectrum antiviral nanomedicines today reminds the strong safety and effectiveness against coronaviruses demonstrated by its lead clinical drug candidate

Flowvpx

EventsRead more...

30 - 01

Jul 2024

3rd Heart Failure Drug Discovery & Development

Boston, MA, USA

30 - 01

Jul 2024

chemical indonesia

jakarta barat, Indonesia

30 - 01

Jul 2024

Inalab 2023

Jakarta Barat, Indonesia

13 - 14

Aug 2024

ADVANCING BUSINESS, TECHNOLOGY AND INNOVATION

Songdo Convensia, Incheon, South Korea

13 - 14

Aug 2024

12 YEARS OF EXCELLENCE: SOUTH KOREA’S BIOLOGICS

Songdo Convensia, Incheon, South Korea

19 - 21

Aug 2024

Biomedical Engineering and Biotechnology

Lisbon, Portugal

19 - 20

Aug 2024

Pharmaceutics, Formulations & Drug Delivery

London, UK

19 - 20

Aug 2024

International Conference on 3D Printing & Additive

Dubai, UAE

Hexagon - Expert Insights Webinar
MFA + MMA 2024
4th Annual Cleaning Validation 2024
2nd Annual Pharma Impurity Conclave 2024
CPHI Korea 2024
World Orphan Drug Congress Europe 2024
Thermo Fisher - Drug Discovery and the impact of mAbs

TOP ARTICLES

  • 3

    Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery

    Dr. Stevan Pecic

    Department of Chemistry and Biochemistry, California State University, Fullerton, USA.

    Xiaohui Weng

    Department of Chemistry and Biochemistry, California State University, Fullerton, USA.

    Michael Gonzalez

    Department of Chemistry and Biochemistry, California State University, Fullerton, USA.

    Arya Emami

    Faculty of Dentistry, University of Toronto, Toronto, Canada.

    Dr. Amir Barzegar Behrooz

    College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipewg, Manitoba, Canada.

    Dr. Rui Vitorino

    Department of Medical Sciences, Institute of Biomedicine-iBiMED, University of Aveiro, Aveiro, Portugal.

    Dr. Saeid Ghavami

    Research Institute of Oncology and Hematology, Cancer Care Manitoba, University of Manitoba, Winnipeg, Canada.

  • 4

    3D Printing Revolutionising Nanotechnology

    Mansi Athalye

    Assistant Professor , Department of Pharmaceutics at L. M. College of Pharmacy

    Sagar Popat

    Research Student, Pursuing M. Pharmacy, Pharmaceutics, L. M. College of Pharmacy

KNOWLEDGE BANK

  • Interviews

    European Lead Factory

    Head of European Screening Centre

    Ton Rijnders is the Head of Screening at the European Lead Factory He holds a PhD in molecular biology and has an extensive experience with drug discovery in pharma with increasing managerial and scientific responsibilities Since November Ton is the General Director of Oncode Institute and has been involved since the very beginning in European Lead Factory via the partner Lygature

  • Articles

    When Orphan Drugs Make All the Difference

    Orphan drugs those medications that are typically produced in small quantities for limited patient populations are growing in importance worldwide Once largely considered too costly to produce given the limited number of patients affected by a particular disease new technology and new breakthroughs in biopharma have changed the landscape allowing more orphan dru

  • Research Insights

    Charge-reversal Nanoparticles: Novel Targeted Drug Delivery Carriers

    AbstractSpurred by significant progress in materials chemistry and drug delivery chargereversal nanocarriers are being developed to deliver anticancer formulations in spatial temporal and dosagecontrolled approaches Chargereversal nanoparticles can release their drug payload in response to specific stimuli that alter the charge on their surface They can e

  • Case Studies

    Pharma Connects On Social: Top 20 Pharmaceutical Companies On Social Media

    AbstractPharmaceutical companies have taken a long time to start using social media in the first place but the industry is still struggling to fully embrace the digital space There are now more than two billion active social media users almost a third of the worlds population Customers are talking about health on the internet and in recent years s

  • Techno Trends

    New Antibiotic by Merck that Fights Bacteria

    In the present drug discovery scenario there are very few pharmaceutical companies who invest in research into antibiotics as majority prefer to focus on profitable drugs for chronic diseases Most drugs were developed years ago and older antibiotics have lost their effect as the bacteria have become resistant to themMerck has developed an antibiotic platensim

Advisory Board

Brian D Smith

Brian D Smith

Nigel Cryer FRSC

Nigel Cryer FRSC

Quang Bui

Quang Bui

Gervasius Samosir

Gervasius Samosir

Tamara Miller

Tamara Miller

Imedla Leslie Rillon

Imedla Leslie Rillon

Andri Kusandri

Andri Kusandri

Nicoleta Grecu

Nicoleta Grecu

Alessio Piccoli

Alessio Piccoli

 .
Pramod Kashid

Pramod Kashid

Neil J Campbell

Neil J

EDITORIAL SECTION